GSK’s RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at increased risk
On Mar. 13, 2026, GSK announced that the US Food and Drug Administration (FDA) has expanded the approved…
On Mar. 13, 2026, GSK announced that the US Food and Drug Administration (FDA) has expanded the approved…
On Jan. 6, 2026, a systematic analysis for the Global Burden of Disease Global study shows that lower…
On Apr. 6, 2020, 3M and the White House announced a plan to import 166.5 million respirators over…
On Mar. 24, 2020, 3M and Ford Motor Co. announced that they had entered into a partnership in…